Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
Completed · Phase 1 · Has a placebo group
Conditions studied: Alzheimer's Disease
In brief
This is a Phase 1 study to examine the safety, tolerability and pharmacokinetics of TC-5619 in elderly subjects with and without Alzheimer's disease. Group 1 includes elderly subjects with Alzheimer's disease to receive TC-5619 or placebo for 28 days to evaluate safety and tolerability. Group 2 includes healthy elderly subjects in a dose escalation design to receive TC-5619 or placebo for 10 days to evaluate safety, tolerability and pharmacokinetics.
Key facts
- Study ID
- NCT01254448
- Run by
- Targacept Inc.
- People needed
- 38
- Starts
- 2010-09-01
- Expected to finish
- 2011-05-01
- Last updated by the study team
- 2013-09-04
Who can join
Age: 55 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Collaborative Neuroscience Network — Long Beach, California, United States
- San Francisco Clinical Research Center — San Francisco, California, United States
- MD Clinical — Hallandale, Florida, United States
- Galiz Research — Miami Springs, Florida, United States
- Comprehensive Phase One — Miramar, Florida, United States
- Compass Research, LLC — Orlando, Florida, United States
- Atlanta Center For Clinical Research — Atlanta, Georgia, United States
- Princeton Medical Institutes — Princeton, New Jersey, United States
- Community Clinical Research — Austin, Texas, United States
- Aspen Clinical Research — Orem, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.